Aequus Pharmaceuticals Inc (AQS) — Cash Flow-to-Debt Ratio
Aequus Pharmaceuticals Inc (AQS) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CA$-21.22K could theoretically repay 0% of its total liabilities (CA$7.09 Million) in one year. See AQS free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aequus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aequus Pharmaceuticals Inc across 12 annual periods. Also explore AQS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aequus Pharmaceuticals Inc (2013–2024)
Year-by-year debt coverage analysis for Aequus Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Aequus Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | CA$-1.66 Million | CA$7.26 Million | ▲ +46.5% |
| 2023 | -0.43x | CA$-2.29 Million | CA$5.38 Million | ▲ +32.9% |
| 2022 | -0.64x | CA$-1.95 Million | CA$3.07 Million | ▼ -38.8% |
| 2021 | -0.46x | CA$-1.17 Million | CA$2.56 Million | ▼ -45.7% |
| 2020 | -0.31x | CA$-804.91K | CA$2.56 Million | ▲ +50.8% |
| 2019 | -0.64x | CA$-1.63 Million | CA$2.55 Million | ▲ +92.2% |
| 2018 | -8.17x | CA$-2.57 Million | CA$314.90K | ▲ +21.3% |
| 2017 | -10.39x | CA$-3.81 Million | CA$366.84K | ▼ -73.2% |
| 2016 | -6.00x | CA$-4.47 Million | CA$744.41K | ▼ -78.9% |
| 2015 | -3.35x | CA$-3.84 Million | CA$1.15 Million | ▼ -82.9% |
| 2014 | -1.83x | CA$-1.36 Million | CA$744.51K | ▲ +88.1% |
| 2013 | -15.44x | CA$-876.06K | CA$56.74K | — |